Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Biologics

AbbVie reports first-ever quarter, downplays Pfizer impact

April 26, 2013

Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much.
 

Europe halts Xeljanz progress

April 26, 2013

European regulators said they're not satisfied that the information they have on hand is enough to let the drug go forward.
 

Pharmas to biotechs: let's make a deal

April 25, 2013

Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.
 

Amgen sales up for the quarter, but biosimilars grab buzz

April 24, 2013

Company revenues were up 5% over last year for the quarter, but much of the Q&A chatter centered around biosimilars.
 

Business Briefs: AstraZeneca, Amgen, BMS and Merck

April 18, 2013

AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off.
 

Recall rebound boosts J&J quarterly results

April 16, 2013

Sales hit $17.5 billion, an 8.5% increase compared to the same period last year.
 

Business briefs: Chandler Chicco, Pfizer, FDA, Dainippon, CDC

April 01, 2013

Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.
 

Business Briefs: Novo, FDA, Biologics

March 19, 2013

Novo's weight-loss news fails to lift investor mood; GAO wants FDA to do more biologics topped 2012 sales.
 

Business briefs: Élan, Teva

February 25, 2013

A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.
 

"I just want to say one word to you: biologics"

October 23, 2012

Biologics are making their way through the FDA approval process at a much faster clip than small molecule drugs these days, and just might unclog pharmas' slow-moving pipelines
 

FDA nods for Teva, J&J signal pipeline progress

August 30, 2012

The FDA gave green lights on two drugs days before the long weekend, and Novartis said Phase III COPD trials are shaping up to lead to regulatory filings.
 

Branded Benlysta DTC campaign ready to roll out

October 26, 2011

New online and print DTC advertising targeting US patients with lupus will appear "within weeks," said executives from Human Genome Sciences. Can the campaign revive blockbuster fortunes for Benlysta?
 

GSK, HGS cleared to launch lupus drug with unrestricted label

March 10, 2011

When co-marketers Human Genome Sciences and GlaxoSmithKline launch newly approved lupus drug Benlysta later this month, reps will be able to tout a broad label.
 

Generic Lovenox drags down Sanofi sales

November 01, 2010

Sanofi-Aventis said US sales of anti-thrombotic Lovenox were cut nearly in half by the launch of generic competition, an indication hospitals are showing little hesitation in using the copycat version.
 

Amgen deploys up to 1,000 reps on Prolia approval

June 03, 2010

Amgen has deployed "500 to 1,000" reps in support of Prolia (denosumab), a biologic osteoporosis treatment that received FDA approval on June 1. The drug was approved in the European Union on May 28.
 

What's behind Humira's bullish forecast?

May 04, 2010

A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.
 

FDA says competing biologic ads both misled

April 07, 2010

One is a sales aid, and one is a consumer brochure, but both ads -- for CSL Behring's Zemaira and for Talecris' Prolastin -- are false or misleading, FDA said in a pair of untitled letters.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising Allergy Anaphylaxis Anti-infective App Approval Centers For Disease Control COPD Diabetes DTC Elan FDA Generic Generic Drugs Lymphoma Marketing & Communications Mobile Oncology Patient Advocacy Pipeline Regulatory Research & Development Roche